Serine Proteinase Inhibitors
"Serine Proteinase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Exogenous or endogenous compounds which inhibit SERINE ENDOPEPTIDASES.
Descriptor ID |
D015842
|
MeSH Number(s) |
D27.505.519.389.745.800
|
Concept/Terms |
Serine Proteinase Inhibitors- Serine Proteinase Inhibitors
- Serine Proteinase Antagonists
- Serine Endopeptidase Inhibitors
- Serine Protease Inhibitors
|
Below are MeSH descriptors whose meaning is more general than "Serine Proteinase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Serine Proteinase Inhibitors".
This graph shows the total number of publications written about "Serine Proteinase Inhibitors" by people in this website by year, and whether "Serine Proteinase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2003 | 0 | 1 | 1 |
2007 | 1 | 1 | 2 |
2009 | 1 | 0 | 1 |
2012 | 1 | 0 | 1 |
2013 | 0 | 1 | 1 |
2015 | 0 | 1 | 1 |
2017 | 10 | 2 | 12 |
2018 | 4 | 2 | 6 |
2019 | 8 | 0 | 8 |
2020 | 3 | 7 | 10 |
2021 | 3 | 0 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Serine Proteinase Inhibitors" by people in Profiles.
-
OFF-State-Specific Inhibition of the Proprotein Convertase Furin. ACS Chem Biol. 2021 09 17; 16(9):1692-1700.
-
The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19. mBio. 2021 08 31; 12(4):e0097021.
-
Identification of 13 Guanidinobenzoyl- or Aminidinobenzoyl-Containing Drugs to Potentially Inhibit TMPRSS2 for COVID-19 Treatment. Int J Mol Sci. 2021 Jun 30; 22(13).
-
Structural Basis of Covalent Inhibitory Mechanism of TMPRSS2-Related Serine Proteases by Camostat. J Virol. 2021 09 09; 95(19):e0086121.
-
A phase I study of high dose camostat mesylate in healthy adults provides a rationale to repurpose the TMPRSS2 inhibitor for the treatment of COVID-19. Clin Transl Sci. 2021 09; 14(5):1967-1976.
-
Targeting the intestinal TMPRSS2 protease to prevent SARS-CoV-2 entry into enterocytes-prospects and challenges. Mol Biol Rep. 2021 May; 48(5):4667-4675.
-
Structure-based phylogeny identifies avoralstat as a TMPRSS2 inhibitor that prevents SARS-CoV-2 infection in mice. J Clin Invest. 2021 05 17; 131(10).
-
Alpha-1 antitrypsin inhibits TMPRSS2 protease activity and SARS-CoV-2 infection. Nat Commun. 2021 03 19; 12(1):1726.
-
Low risk of the TMPRSS2 inhibitor camostat mesylate and its metabolite GBPA to act as perpetrators of drug-drug interactions. Chem Biol Interact. 2021 Apr 01; 338:109428.
-
Field-Template, QSAR, Ensemble Molecular Docking, and 3D-RISM Solvation Studies Expose Potential of FDA-Approved Marine Drugs as SARS-CoVID-2 Main Protease Inhibitors. Molecules. 2021 Feb 10; 26(4).